Peer Exchange

Advanced Endometrial Cancer: Treatment Optimization

November 22nd 2022

A panel of esteemed nurse practitioners discusses how endometrial cancer is diagnosed, the process of treatment decision-making, and the management of adverse effects in patients undergoing treatment.

Optimizing Therapy for Ovarian Cancer: Recent Data Highlights

October 6th 2022

A panel of esteemed physicians review recent key data updates in ovarian cancer from ESMO 2022, including late-breaking news.

The Evolving Treatment Paradigm for Stage I-IIIA NSCLC

October 5th 2022

A multidisciplinary panel discusses recent updates and advances in molecular testing and treatment for stage I-IIIA non-small cell lung cancer (NSCLC).

The Evolving Treatment Paradigm of Hepatocellular Carcinoma: An Expert Case-based Discussion

September 30th 2022

Centering discussion on clinical trial data and real-world patient profiles, expert oncologists review the treatment paradigm for hepatocellular carcinoma and consider how they would sequence therapy.

The Evolving Treatment Landscape of Renal Cell Carcinoma: Highlights from ESMO 2022 and Beyond

September 29th 2022

In the context of recent and ongoing clinical trials, expert oncologists provide comprehensive insight to the evolving treatment landscape of both clear cell and non–clear cell advanced RCC.

Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice

September 28th 2022

A global panel of experts discusses several recent data updates on the role of immunotherapy in non-small cell lung cancer (NSCLC) and their impact on clinical practice.

Test Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond

September 27th 2022

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

Addressing Disparities in Multiple Myeloma Care Among Racial and Ethnic Minority Populations

September 23rd 2022

Expert panelists share insight on factors that lead to disparities in the management of multiple myeloma among racial and ethnic minority groups and strategies to address these disparities.

The Evolving Landscape of Biliary Tract Cancers

September 21st 2022

Expert panelists review the current treatment landscape of biliary tract cancers and consider how the field may evolve in light of novel therapeutic strategies in the pipeline.

HER2 Alterations in Non-Small Cell Lung Cancer

September 12th 2022

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

The Evolving Field of Biomarker Testing in Solid Tumors

August 29th 2022

A panel of experts discusses molecular testing and the use of targeted agents in lung and breast cancers, including best practices for ordering testing and how to factor results into treatment decisions.

ADCs in the Treatment of Breast Cancer and Gastric Cancer and Managing AEs Associated with ADCs

August 19th 2022

A panel of experts in oncology review the use of antibody drug conjugates (ADCs) in breast and gastric cancers, defining optimal management of ADC-related adverse events.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®

Recent Advances in the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

July 15th 2022

A distinguished panel of experts in hematologic malignancies builds a lively discussion on recent clinical trials and potential advancements in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

The Expanding Field of GVHD

July 11th 2022

Expert panelists elucidate the evolving field of graft versus host disease management, highlighting novel therapies and treatment approaches.

Advances in Treatment and Management of Immune Thrombocytopenia

June 30th 2022

Expert panelists review new data on the management of immune thrombocytopenia and consider how these data may impact clinical practice.

Applying New Data to Treatment Selection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

June 30th 2022

A panel of experts discusses newly presented data from ASCO 2022 and how it affects potential treatment approaches for relapsed/refractory DLBCL.

A New Wave of Progress in The Treatment of Multiple Myeloma: Translating Evidence to Clinical Practice

June 30th 2022

Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.

Current and Future Trends in Myeloproliferative Neoplasms

June 29th 2022

An expert panel discusses recent updates in the treatment of myeloproliferative neoplasms from ASCO 2022.

Emerging Treatment Considerations in HCC: An Expert Case-Based Discussion

June 29th 2022

Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

June 28th 2022

Expert oncologists Benjamin Levy, MD; Chaitali Nangia, MD; Jessica Donington, MD; Jonathan Wesley Riess, MD; Alexander Spira, MD; and Heather Wakelee, MD, review data from ASCO 2022 and updates in the management of NSCLC.